CDK12突变型前列腺癌的单中心临床病理特征分析  

Analysis of the clinicopathological characteristics of CDK12-mutant prostate cancer in a single center

作　　者：樊俊杰 蒋凡 贺大林[1] 李磊[1] 谢宏俊 田鸽[1] 吴开杰[1] FAN Jun-jie;JIANG Fan;HE Da-lin(Department of Urology, the First Affiliated Hospital of Xi′an Jiaotong University, Shanxi 710061, China)

机构地区：[1]西安交通大学第一附属医院泌尿外科,陕西710061 [2]宝鸡市中心医院泌尿外科,陕西721300

出　　处：《中国临床新医学》2021年第7期663-667,共5页CHINESE JOURNAL OF NEW CLINICAL MEDICINE

基　　金：吴阶平医学基金会临床科研专项资助基金项目(编号:320.6750.2020-14-11)。

摘　　要：目的探讨细胞周期依赖性蛋白12(CDK12)突变型前列腺癌的临床病理特征、突变类型及治疗方式。方法报告10例CDK12突变型前列腺癌患者的临床病理特征、基因检测结果和随访资料,复习相关文献并进行讨论。结果10例患者平均确诊年龄为(66.60±6.80)岁,平均血清前列腺特异性抗原为652.19 ng/ml,并且穿刺Gleason评分均≥8分,8例患者确诊时已出现远处转移。此外,6例患者的CDK12突变发生在去势抵抗阶段。结论CDK12突变型前列腺癌恶性程度较高且易进展至去势抵抗,该部分患者可能会从铂类化疗、聚ADP核糖聚合酶(PARP)抑制剂或免疫治疗中获益。Objective To investigate the clinicopathological characteristics,types of mutation and treatment methods of cell cycle-dependent kinase 12(CDK12)-mutant prostate cancer(PCa).Methods The clinicopathological characteristics,gene mutation results and follow-up data of 10 patients with CDK12-mutant PCa were reported,and the related literature was reviewed and discussed.Results The mean age of the 10 patients with a definite diagnosis was(66.60±6.80)years,and their mean serum prostate-specific antigen was 652.19 ng/ml,and their Gleason scores of puncture were more than or equal to 8 points.Of the 10 patients,eight had distant metastasis at the time of diagnosis.In addition,CDK 12 mutation occurred in castration-resistant stage in 6 patients.Conclusion Patients with CDK12-mutant PCa,which has a high degree of malignancy and is prone to castration-resistant stage,may benefit from platinum-based chemotherapy,poly ADP-ribose polymerase(PARP)inhibitors or immunotherapy.

关 键 词：前列腺癌 细胞周期依赖性蛋白12突变 临床病理特征 治疗 预后 

分 类 号：R737.25[医药卫生—肿瘤]